Approved for use through 04/30/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE cond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to Complete If Known Substitute for form 1449/PTO Application Number 10/583,056 INFORMATION DISCLOSURE March 16, 2007 Filing Date STATEMENT BY APPLICANT Katherine S. Bowdish First Named Inventor Art Unit 1644 (Use as many sheets as necessary) G. R. Ewoldt Examiner Name 4 ALEX-P01-112

Attorney Docket Number

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AD*	US-6,605,279-B2	08-12-2003	Freeman et al.	
	AE*	US-20030134297	07-17-2003	Olson et al.	
	AF*	US-6,548,275	04-15-2003	Goldenberg	
	AG*	US-7,285,642	10-06-2005	Figdor et al.	1
					1
1					1

		FOREIG	GN PATENT	DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>6</sup> -Kind Code <sup>5</sup> (# known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	T°
	ВН	WO-95/032734	12-07-1995	Innogenetics NV		П
	ВІ	WO-00/63251	10-26-2000	Univ Nijmegen et al.		
	вЈ	WO-02/50119	06-27-2002	Stichting Katholieke Universiteit		П

Examiner	Date	
Signature	Conside	red

EXAMINE hitsil intervence considered, whether or not clusten is a conformance with MEP 90. Once lies through cluster. If not in conformance and not continued by the conformance and not continued by the conformance and not conformance to the Clin No are not supplied under 37 CFR 1 98(a)(2)(a)(b) because that application was filled after June 30, 2003 or is available in the PM - Applicant upon the Clin PM - Applicant content in gradual conformance and personal content in gradual conformance and personal content in gradual content in gradual conformance and personal c

Sheet

of

Approved for use through 04/30/2000 (MM) 0653-0031
U.S. Patent and Trademark Office, U.S. (EPARTIMENT OF COMMERCE
Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless a contains a valid Office control number.

Sul	estitute for form 1449/PTO			Complete if Known		
				Application Number	10/583,056	
11	<b>VEORMATION</b>	I DI	SCLOSURE	Filing Date	March 16, 2007	
l s	TATEMENT I	3Y /	APPLICANT	First Named Inventor	Katherine S. Bowdish	
				Art Unit	1644	
	(Use as many sh	eets a:	s necessary)	Examiner Name	G. R. Ewoldt	
Sheet	2	of	4	Attorney Docket Number	ALEX-P01-112	

		NON PATENT LITERATURE DOCUMENTS	
Examiņer Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CC1	Purified Mouse Anti-Human Monoclonal Antibody, BD PharMingen Technical Data Sheet, BD Biosciences Product Information sheet, Catalog Number 551186, 05/01/01.	
	CD1	Amersdorfer et al., Molecular Characterization of Murine Humoral Immune Response to Botulinum Neurotoxin Type A Binding Domain as Assessed by Using Phage Antibody Libraries, Infection and Immunity, 65, pp. 3743-3752 (1997)	
	CE1	Ahsan et al., Immunopathogenesis of Human Immunodeficiency Virus. Seminars in Nephrology, Vol. 18, No. 4, pages 422-435 (1998)	Г
	CF1	Berkower, I., et al., "CHIMERIC HIV-1 ENVELOPE GP120-HEPATITIS B CORE ANTIGEN (HbcAg) FUSION PROTEINS FOR HIV-1 VACCINES," FASEB Journal, 10(6):A1082 (1996).	Г
	CG1	Eck J., et al., "Cloning of the Mistletoe Lectin Gene and Characterization of the Recombinant A-Chain," European Journal of Biochemistry, 264:775-784 (1999).	Г
	CH1	FDA Approves Second Indication for Monolclonal Antibody, June 28, 1993, printed on November 12, 2004 from http://www.fda.gov/bbs/topics/ANSWERS/ANS00506.html, June 28, 1993.	
	CI1	Fè d'Ostiani, C., et al., "Dendritic Cells Discriminate between Yeasts and Hyphae of the Fungus Candida albicans: Implications for Initiation of T Helper Cell Immunity In Vitro and In Vivo," J. Exp. Med., 191(10):1661-1673 (2000).	
	CJ1	Forsyth, C. B., et al., "Interaction of the Fungal Pathogen Candida albicans with Integrin CD11b/CD18: Recognition by the I Domain is Modulated by the Lectin-Like Domain and the CD18 Subunit," The Journal of Immunology, 161:6196-6205 (1998)	
	CK1	Fumero et al., Immunosuppressive drugs as an adjuvant to HIV treatment. Journal of Antimicrobial Chemotherapy Vol. 53, pages 415-417 (2004)	Г
	CL1	Harlow and Lane, Antibodies, A Laboratory Manual. 1988 Cold Spring Harbor Laboratory, pages 141-142	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional) <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached

Approved for use through 04:30:2003 ONE 05:50:00

U.S. Patent and Trademan Office; U.S. DEPARTINENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless i contained a valid CMIS control number.

Sub	stitute for form 1449/PTO			Complete if Known		
				Application Number	10/583,056	
II.	<b>VEORMATION</b>	I DI	SCLOSURE	Filing Date	March 16, 2007	
s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Katherine S. Bowdish	
				Art Unit	1644	
	(Use as many she	ets a	necessary)	Examiner Name	G. R. Ewoldt	
Sheet	Sheet 3 of 4		Attorney Docket Number	ALEX-P01-112		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), dete, page(s), volume-issue number(s), publisher, city and/or country where published.	T°
	СМ1	Kataoka et al., Cancer Research, 38(5), pp. 1202-1207 (1978) - Abstract only from Biosis database.	
	CN1	Marth, T., et al., "Regulation of Interleukin-12 by Complement Receptor 3 Signaling," The Journal of Experimental Medicine, 185(11):1987-1995 (1997).	
	CO1	Murdoch et al., Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Research and Therapy 4:9 (2007)	
	CP1	Netea, M. G., et al., "Immune sensing of Candida alblcans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors," The Journal of Clinical Investigation, 116(6):1642-1650 (2006).	П
	CQ1	Package insert for Orthoclone OKT3 Sterile Solution (murumonab-CD3) from Ortho Biotech Products LP, Raritan, NJ, Revised March 2001.	
	CR1	Product Information for Affinity Purilled anti-human CD209 (DC-SIGN) antibody, from eBioscience, printed on January 5, 2004 from http://www.bioscience.com/ebioscience/specs/antibody 14/14-2099.htm	
	CS1	Rosati et al., Cytokine Response to Inactivated Candida albicans in Mice. Cell. Immunol., 162:256-264 (1995)	
	CT1	Sequence Alignment of Curtis et al., PNAS 89: 8356-8360 (1992) with SEQ ID NO: 2 from U.S.S.N. 09/719,961.	
	CU1	Stephen Smith. The patogenesis of HIV infection: stupid may not be so dumb after all. Retrovirology 3:60 (2006)	
	CV1	Steinbrook, R., "One Step Forward, Two Steps Back - Will There Ever Be an AIDS Vaccine?," N. Engl. J. Med., 357:2653-2655 (2007).	

Examiner Signature		Date Considered	
	Initial if reference considered, whether or not citation is in conformance with MPEP 609. Include copy of this form with next communication to applicant	Draw line through cit	tation if not in conformance and not

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached

PTO SS 056 (G-09)
Approved for use through 04/30/2009 OMB 0561-0031
U.S. Paters and Trademark Office; U.S. DEPARTIMENT OF COMMERGE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Sub	stitute for form 1449/PTO			Complete if Known		
				Application Number	10/583,056	
11	<b>VEORMATION</b>	1 DI	SCLOSURE	Filing Date	March 16, 2007	
l s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Katherine S. Bowdish	
				Art Unit	1644	
	(Use as many she	eets a:	s necessary)	Examiner Name	G. R. Ewoldt	
Sheet	4	of	4	Attorney Docket Number	ALEX-P01-112	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Tº
	CW1	Szabo, I., et al., "Modulation of Macrophage Phagocytic Activity by Cell Wall Components of Candida albicans," Cellular Immunology, 164:182-188 (1995).	
	CX1	Taken, P.J., et al., "Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody," Blood, 106(4):1278-1285 (2005).	
	CY1	Vakeva, Antti, P., et al., "Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion," Circulation, 97, pp. 2259-2267 (1998).	
	CZ1	Woodle, E.S., et al., Phase 1 Trial of Humanized, Fe Receptor Nonbinding OKT3 Antibody, huOKT3 <sub>11</sub> (Ala-Ala) in the Treatment of Acute Renal Allograft Rejection. Translplantation, 68, pp. 608-616 (1999).	
	CA2	Yan et al., "b-Glucan, a "Specific" Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3 (CD11b/CD18)," The Journal of Immunology, 163(6):3045-3052 (1999).	
			H

Signature	Considered
*EXAMINER initial if reference considered, whether or not citation is in conformance with MPEP 60 considered. Include copy of this form with next communication to applicant.	Draw line through citation if not in conformance and not

Date

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached

Examiner